Jon Olson, MD
Neurology · Baton Rouge, LANPI 1619966819
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.1% of the total across 1,044 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 54 manufacturers, the largest accounting for just 15.1% — the pattern of someone who eats at a lot of different presentations.
Across 1,044 payments — averaging $18.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Biogen$1K
- Novocure Inc.$1K
- Amgen$1K
- Pfizer$910
- UCB, Inc.$818
- plus $11K from 48 others
Across 113 payments — averaging $14,490 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$1.1M
- Sanofi$326K
- Genentech, Inc.$131K
- Novocure GmbH$120K
What the payments were for
- Consulting fees$4502%
- Speaking & faculty fees$2551%
- Food & beverage$18,23496%
- Education$310%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,971 in reported general payments places this provider in the 85th percentile of 225 neurology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 55 | $490,360 |
| SolirisEculizumab | 11 | $464,265 |
| ImbruvicaIbrutinib | 12 | $194,337 |
| VumerityDiroximel Fumarate | 11 | $103,462 |
| Nurtec OdtRimegepant Sulfate | 40 | $89,383 |
| CopaxoneGlatiramer Acetate | 13 | $84,790 |
| Teriflunomide | 22 | $81,614 |
| QuliptaAtogepant | 46 | $60,199 |
| Dimethyl Fumarate | 48 | $52,227 |
| UbrelvyUbrogepant | 32 | $35,064 |
| Dalfampridine ErDalfampridine | 40 | $17,510 |
| Aimovig AutoinjectorErenumab-Aooe | 18 | $14,363 |
| Keppra XrLevetiracetam | 11 | $13,885 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 16 | $13,450 |
| ExelonRivastigmine | 12 | $8,103 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaSoliris | $694 | $464,26511 claims |
| BiogenVumerity | $1,342 | $103,46211 claims |
| AbbVieQulipta, Ubrelvy | $2,855 | $95,26378 claims |
| PfizerNurtec Odt | $910 | $89,38340 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $482 | $84,79013 claims |
| NovartisExelon | $630 | $8,10312 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $203 | $2,26833 claims |
| Upsher-smith Laboratories LLCTopiramate | $25 | $1,381138 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 225 neurology providers in Louisiana.
Other neurology in Baton Rouge
- Kevin CallerameBaton Rouge$420K
- Gerald CaleganBaton Rouge$400K
- Benjamin KidderBaton Rouge$35K
- Joseph AcostaBaton Rouge$33K
- William GladneyBaton Rouge$19K
- David GlossBaton Rouge$15K
- Meghan HarrisShreveport$553K
- Maria Carmen WilsonCovington$295K
- John EnglandNew Orleans$268K
- Ariel Antezana AntezanaAlexandria$253K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.